Cadence Capital Management’s Enzo Biochem, Inc. ENZ Stock Holding History

Cadence Capital Management’s Portfolio ENZ Stock Details ENZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-172,844	Closed	-$897K	–	718
2018 Q2	$897K	Buy	172,844 +18,656	+12%	+$114K	0.05%	412
2018 Q1	$845K	Buy	154,188 +65,558	+74%	+$462K	0.06%	419
2017 Q4	$722K	Buy	+88,630	New	+$846K	0.05%	430

Other funds holding ENZ

EGA

Evermore Global Advisors Summit, New Jersey $26.3M AUM 7.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

RAM

Roumell Asset Management Chevy Chase, Maryland $53.3M AUM 8.91% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Cadence Capital Management's ENZ Position: Q3 2018 in Review

Cadence Capital Management sold out of Enzo Biochem, Inc. (ENZ) in Q3 2018, closing a stake of 172,844 shares — an estimated $897K sold.

Cadence Capital Management first reported a position in ENZ in Q4 2017 and held it in 3 quarters. The position peaked at $897K in Q2 2018. 101 funds tracked by Wall St. Rank hold ENZ as of Q3 2018.

Cadence Capital Management reported no remaining Enzo Biochem, Inc. position as of Q3 2018 after selling out during the quarter.
Cadence Capital Management sold 172,844 Enzo Biochem, Inc. shares in Q3 2018, an estimated $897K.
Cadence Capital Management first reported a position in Enzo Biochem, Inc. in Q4 2017 and held it in 3 quarters.
Cadence Capital Management's Enzo Biochem, Inc. position peaked at $897K in Q2 2018.
101 funds tracked by Wall St. Rank held Enzo Biochem, Inc. as of Q3 2018.

Based on Cadence Capital Management's 13F filing for Q3 2018, filed 2 Nov 2018.